secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001104659-24-092495
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar to restate financial statements, receives Nasdaq delinquency notice for late Q2 filing
--------------------------------------------------------------------------------

- Restating audited FY2022 & FY2023 and unaudited Q1-Q3 2023 & Q1 2024 due to warrant accounting error in Oct 2022 financing.
- Changes are non-cash and non-operating; restatement expected to take ~6 weeks before filing Q2 2024 10-Q.
- Received Nasdaq notice on Aug 20, 2024 for late Q2 10-Q; must submit compliance plan by Oct 21, 2024.
- Nasdaq may grant up to 180-day extension (until Feb 17, 2025) if plan accepted; otherwise can appeal.
- No immediate delisting impact, but failure to regain compliance could lead to listing suspension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924092495/0001104659-24-092495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924092495/tm2422595d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-092495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer